These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 19124393)

  • 1. Renin-angiotensin-aldosterone system intervention in the cardiometabolic syndrome and cardio-renal protection.
    Whaley-Connell A; Pavey BS; Chaudhary K; Saab G; Sowers JR
    Ther Adv Cardiovasc Dis; 2007 Oct; 1(1):27-35. PubMed ID: 19124393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obesity, cardiometabolic syndrome, and chronic kidney disease: the weight of the evidence.
    Lastra G; Manrique C; Sowers JR
    Adv Chronic Kidney Dis; 2006 Oct; 13(4):365-73. PubMed ID: 17045222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of the renin-angiotensin system in the pathophysiology, prevention, and treatment of renal impairment in patients with the cardiometabolic syndrome or its components.
    Alpert MA; Govindarajan G; Del Rosario ML; Reisin E
    J Cardiometab Syndr; 2009; 4(1):57-62. PubMed ID: 19245518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of obesity and its bioclinical correlates in the progression of chronic kidney disease.
    Chalmers L; Kaskel FJ; Bamgbola O
    Adv Chronic Kidney Dis; 2006 Oct; 13(4):352-64. PubMed ID: 17045221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship between hyperinsulinemia, hypertension and progressive renal disease.
    El-Atat FA; Stas SN; McFarlane SI; Sowers JR
    J Am Soc Nephrol; 2004 Nov; 15(11):2816-27. PubMed ID: 15504934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications.
    Cooper ME
    Am J Hypertens; 2004 Nov; 17(11 Pt 2):16S-20S; quiz A2-4. PubMed ID: 15539106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renin-angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans.
    Sarzani R; Salvi F; Dessì-Fulgheri P; Rappelli A
    J Hypertens; 2008 May; 26(5):831-43. PubMed ID: 18398321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin receptor blockers: novel role in high-risk patients.
    Javed U; Deedwania PC
    Cardiol Clin; 2008 Nov; 26(4):507-26. PubMed ID: 18929228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic syndrome and kidney disease.
    Ritz E
    Blood Purif; 2008; 26(1):59-62. PubMed ID: 18182798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of hypertension in the cardiometabolic syndrome.
    Redon J; Cifkova R; Laurent S; Nilsson P; Narkiewicz K; Erdine S; Mancia G
    J Hypertens; 2009 Mar; 27(3):441-51. PubMed ID: 19262221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insights into the biology of diabetic vascular disease: what's new?
    Sowers JR; Stump CS
    Am J Hypertens; 2004 Nov; 17(11 Pt 2):2S-6S; quiz A2-4. PubMed ID: 15539107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin II receptor blockers in the treatment of the cardiovascular disease continuum.
    Chrysant SG
    Clin Ther; 2008; 30 Pt 2():2181-90. PubMed ID: 19281913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal disease in obesity: the need for greater attention.
    Rutkowski P; Klassen A; Sebekova K; Bahner U; Heidland A
    J Ren Nutr; 2006 Jul; 16(3):216-23. PubMed ID: 16825023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The endothelin system and its antagonism in chronic kidney disease.
    Dhaun N; Goddard J; Webb DJ
    J Am Soc Nephrol; 2006 Apr; 17(4):943-55. PubMed ID: 16540557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of the renin-angiotensin-aldosterone system in cardiovascular progenitor cell function.
    Qian C; Schoemaker RG; van Gilst WH; Roks AJ
    Clin Sci (Lond); 2009 Feb; 116(4):301-14. PubMed ID: 19138171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mineralocorticoid receptor activation in obesity hypertension.
    Nagase M; Fujita T
    Hypertens Res; 2009 Aug; 32(8):649-57. PubMed ID: 19521418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Supratherapeutic doses of angiotensin receptor blockers to decrease proteinuria in patients with chronic kidney disease.
    Palmer BF
    Am J Nephrol; 2008; 28(3):381-90. PubMed ID: 18063856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of the renin-angiotensin-aldosterone system and inflammatory processes in the development and progression of diastolic dysfunction.
    Sciarretta S; Paneni F; Palano F; Chin D; Tocci G; Rubattu S; Volpe M
    Clin Sci (Lond); 2009 Mar; 116(6):467-77. PubMed ID: 19200056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Overweight and obesity--risk factors in the development and progression of renal disease].
    Sebeková K; Klassen A; Bahner U; Heidland A
    Vnitr Lek; 2004 Jul; 50(7):544-9. PubMed ID: 15323263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heart and kidney: fatal twins?
    Ritz E
    Am J Med; 2006 May; 119(5 Suppl 1):S31-9. PubMed ID: 16563946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.